In this article, Ian Chan, Chief Executive Officer and Co-Founder of biotech company Abpro, discusses the development of neutralising antibodies for SARS-CoV-2. Abpro’s neutralising antibody candidate ABP 300 is currently in Phase II/III trials.
List view / Grid view
US Food and Drug Administration (FDA)
Filter the results
Through a series of experiments, researchers have identified small drug molecules that can inhibit filoviruses such as Ebola and Marburg.
According to scientists, maternal cells act as a reservoir for Zika, enabling the virus to pass from mother to foetus during pregnancy.
Analysis reveals people taking nucleoside reverse transcriptase inhibitors are significantly less likely to develop dry macular degeneration, a leading cause of age-related vision loss.
The N439K mutation improves the interaction between SARS-CoV-2 Spike protein and the viral receptor ACE2 and eludes antibody-mediated immunity, say investigators.
The lead candidate, ADG2, was able to neutralise SARS-CoV and various strains of SARS-CoV-2, including those that are resistant to currently available antibody treatments.
Investigators found that red propolis can kill schistosomes at all stages of development and therefore suggest it could be highly effective for treating schistosomiasis.
Researchers have been tracking SARS-CoV-2 by sequencing the genomes of virus samples collected from diagnostic testing. They hope that using next generation sequencing (NGS) on SARS-CoV-2 will help to accurately diagnose the novel coronavirus, identify mutations and track its history. This article explores the findings of their latest study and…
Glycosaminoglycans (GAGs) are a class of naturally occurring polysaccharides that play vital roles in cellular functions. GAGs (eg, hyaluronic acid, heparosan, chondroitin, chondroitin sulfate, heparan sulfate and heparin) have also been utilised in biopharmaceutical and nutraceutical industries. Animal-sourced GAGs can contain process impurities and contaminants, which may result in adverse…
According to a new study, blood clots in patients with severe COVID-19 are caused by an autoimmune antibody that circulates in the blood and attacks cells.
Exploring how the Ebola virus develops remdesivir resistance has highlighted a mutation that could allow SARS-CoV-2 to do the same.
Scientists have demonstrated that AR-12 can inhibit SARS-CoV-2 replication and are working to initiate clinical trials evaluating the antiviral drug.
There are currently no licenced pharmaceuticals to treat cocaine addiction. To overcome this issue, US researchers at the University of Alabama at Birmingham have been exploring how cocaine alters transcription in the nucleus accumbens, a region of the brain implicated in compulsive drug use. Here, Hannah Balfour discusses with Dr…
As the global COVID-19 situation is rapidly changing, staying abreast with the latest news can be challenging. In this article, Sheraz Gul provides an overview of the broad range of potential treatments in development and discusses how the regulatory landscape can shift at any time.